WO2016020936A3 - A novel oral gastroretentive pharmaceutical dosage form - Google Patents

A novel oral gastroretentive pharmaceutical dosage form Download PDF

Info

Publication number
WO2016020936A3
WO2016020936A3 PCT/IN2015/050070 IN2015050070W WO2016020936A3 WO 2016020936 A3 WO2016020936 A3 WO 2016020936A3 IN 2015050070 W IN2015050070 W IN 2015050070W WO 2016020936 A3 WO2016020936 A3 WO 2016020936A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
same
pharmaceutical dosage
different
novel oral
Prior art date
Application number
PCT/IN2015/050070
Other languages
French (fr)
Other versions
WO2016020936A2 (en
Inventor
Jayendrakumar Dasharathlal PATEL
Shwetaben Dasharathlal PATEL
Original Assignee
Patel Jayendrakumar Dasharathlal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patel Jayendrakumar Dasharathlal filed Critical Patel Jayendrakumar Dasharathlal
Publication of WO2016020936A2 publication Critical patent/WO2016020936A2/en
Publication of WO2016020936A3 publication Critical patent/WO2016020936A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Abstract

A novel oral gastroretentive pharmaceutical dosage form and methods for preparing a novel oral gastroretentive pharmaceutical dosage form are described in present invention. A present inventions also provide a novel gastroretentive dosage form that deliver one or more active substances at same or different release rate by same or different release mechanism for same or different period of time in same or different region of gastrointestinal tract from single drug delivery system, i.e. a dosage form that is relatively flexible with respect to how to obtain a desired release pattern of the same or different active substances.
PCT/IN2015/050070 2014-07-21 2015-07-21 A novel oral gastroretentive pharmaceutical dosage form WO2016020936A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2338MU2014 2014-07-21
IN2338/MUM/2014 2014-07-21

Publications (2)

Publication Number Publication Date
WO2016020936A2 WO2016020936A2 (en) 2016-02-11
WO2016020936A3 true WO2016020936A3 (en) 2016-05-26

Family

ID=55264729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/050070 WO2016020936A2 (en) 2014-07-21 2015-07-21 A novel oral gastroretentive pharmaceutical dosage form

Country Status (1)

Country Link
WO (1) WO2016020936A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309404B (en) * 2016-10-27 2019-10-25 四川省百草生物药业有限公司 A kind of sertraline hydrochloride capsules of high stability and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001113A1 (en) * 1997-07-01 1999-01-14 Pfizer Products Inc. Gelatine encapsulated solution dosage forms of sertraline
WO2001047498A2 (en) * 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
US6517866B1 (en) * 1997-07-01 2003-02-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001113A1 (en) * 1997-07-01 1999-01-14 Pfizer Products Inc. Gelatine encapsulated solution dosage forms of sertraline
US6517866B1 (en) * 1997-07-01 2003-02-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
WO2001047498A2 (en) * 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method

Also Published As

Publication number Publication date
WO2016020936A2 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
IL258464A (en) Pharmaceutical formulations for the oral delivery of peptide drugs
IL251462A0 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs
EP4233978A3 (en) Oral delivery of active drug substances
WO2017091749A8 (en) Shape changing drug delivery devices and methods
JP2015057451A5 (en)
MX2013006591A (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
EP3498264A4 (en) Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets
BR112017028140A2 (en) pharmaceutical formulations
MX2017003561A (en) Compositions and methods for cannabinoid coatings for use in drug delivery.
PH12015500823A1 (en) Modified release formulations for oprozomib
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
PL3793534T3 (en) An oral tablet for delivery of active ingredients to the gastrointestinal tract
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
CR20140358A (en) DRUG ADMINISTRATION SYSTEM
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MX353623B (en) Drug delivery system.
MX2017013950A (en) Zolmitriptan powders for pulmonary delivery.
WO2015001541A3 (en) Pharmaceutical film composition
WO2016020936A3 (en) A novel oral gastroretentive pharmaceutical dosage form
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
MX2018011685A (en) Process for mesalazine solid formulations.
IN2014MU00043A (en)
UY37413A (en) OPROZOMIB IMMEDIATE RELEASE FORMULATIONS
PH12016502527B1 (en) Stabilized desmopressin

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15830135

Country of ref document: EP

Kind code of ref document: A2